Tenpoint Therapeutics unlocks a £170m Series B from investors to rejuvenate vision in the aging eye

Tenpoint Therapeutics develops treatments for age-related eye conditions. Its products are designed to address presbyopia and other vision issues through clinically developed ophthalmic therapies.